Local nasal immunotherapy with birch pollen-galactomannan conjugate-containing ointment in mice and humans

  • Komatsuzaki Keiko
    Department of Respiratory Medicine, Tokyo Medical and Dental University
  • Kageshima Hiroki
    Bio & Healthcare Business Division, Wako Filter Technology Co., Ltd.
  • Sekino Yuki
    Bio & Healthcare Business Division, Wako Filter Technology Co., Ltd.
  • Suzuki Yasuhiro
    Department of Otorhinolaryngology, Tokyo Medical and Dental University
  • Ugajin Tsukasa
    Department of Dermatology, Tokyo Medical and Dental University
  • Tamaoka Meiyo
    Department of Respiratory Medicine, Tokyo Medical and Dental University
  • Hanazawa Ryoichi
    Department of Clinical Biostatistics, Tokyo Medical and Dental University
  • Hirakawa Akihiro
    Department of Clinical Biostatistics, Tokyo Medical and Dental University
  • Miyazaki Yasunari
    Department of Respiratory Medicine, Tokyo Medical and Dental University

抄録

<p>Background: Allergen immunotherapy (AIT) is the only disease-modifying treatment for immunoglobulin (Ig) E-mediated allergy. Owing to the high prevalence and early onset of hay fever and pollen-food allergy syndrome (PFAS), a safer and simpler treatment method than conventional AIT is needed. To develop a local nasal immunotherapy using an ointment containing hypoallergenic pollen and assess its efficacy in mice and healthy humans.</p><p>Methods: Hypoallergenicity was achieved by combining pollen and galactomannan through the Maillard reaction to create birch pollen-galactomannan conjugate (BP-GMC). The binding of galactomannan to Bet v 1 was confirmed using electrophoresis and Western blotting (WB). Binding of specific IgE antibodies to BP-GMC was verified using enzyme-linked immunosorbent assay (ELISA) and basophil activation test (BAT). The localization of BP-GMC absorption was confirmed using a BALB/c mouse model. BP-GMC mixed with white petrolatum was intranasally administered to 10 healthy individuals (active drugs, 8; placebo, 2) for 14 days.</p><p>Results: In electrophoresis and WB, no 17-kDa band was observed. In ELISA and BAT, BP-GMC did not react to specific IgE but was bound to IgA and IgG. In the mouse model, BP-GMC was detected in nasopharyngeal-associated lymphoid tissues. In the active drug group, the salivary-specific IgA level significantly increased on day 15 (p = 0.0299), while the serum-specific IgG level significantly increased on day 85 (p = 0.0006).</p><p>Conclusions: The BP-GMC ointment rapidly produced antagonistic antibodies against IgE; it is safe and easy to use and might serve as a therapeutic antigen for hay fever and PFAS.</p>

収録刊行物

参考文献 (39)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ